



NDA 213973/S-010

**SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING
REQUIREMENT**

Deciphera Pharmaceuticals, LLC
Attention: Gurleen Kaur
Manager, Regulatory Affairs
200 Smith Street
Waltham, MA 02451

Dear Gurleen Kaur:

Please refer to your March 25, 2025, supplemental new drug application (sNDA) and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Qinlock (ripetinib) tablets.

This Prior Approval sNDA amended the Qinlock (ripetinib) Prescribing Information (PI) in the following sections:

- Section 5.4 Cardiac Dysfunction – correction of Grade 3 ejection fraction data from the pooled safety population and the INVICTUS study;
- Section 12.3 Drug Interaction Studies – updated information regarding concomitant use of ripetinib and a sensitive CYP2C8 substrate

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplemental application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We have received your submission dated March 21, 2025, containing the final report for the following postmarketing requirement listed in the May 15, 2020, approval letter.

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

3834-2 Conduct a clinical pharmacokinetic trial to evaluate the effect of repeat doses of ripretinib on the single dose pharmacokinetics of a sensitive CYP2C8 substrate. This trial should be designed and conducted in accordance with the FDA Guidance for Industry titled, "Clinical Drug Interaction Studies – Study Design, Data Analysis, and Clinical Implications." The results from this trial should determine the magnitude of increase in the exposure of the CYP2C8 substrate and an appropriate dosing recommendation of CYP2C8 substrates when they are administered concomitantly with ripretinib and may inform labeling.

We have reviewed your submission and conclude that the above requirement was fulfilled.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our May 15, 2020, letter. You are not required to report on the status of closed (released or fulfilled) PMRs/PMC in your annual report required under 21 CFR 601.70 of the FD&CA.

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Craig Long, Regulatory Health Project Manager, at 301-837-7646 or email at Craig.Long@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Steven Lemery, M.D., M.H.S.
Director
Division of Oncology 3
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
 - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

STEVEN J LEMERY
05/06/2025 02:41:11 PM